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Dear Larner College of Medicine Research Committee, 
 
This summer I had the privilege of working in the Stein/Lian Lab in Department of Biochemistry under the 
guidance of Dr. Andrew Fritz. I would like to express my sincerest thanks to several parties: to the Research Committee 
and College of Medicine Alumni for facilitating this excellent opportunity and supporting my work; to Drs. Gary Stein, 
Janet Stein, and Jane Lian for the time and resources they graciously provided to help me develop my project in their 
lab; and to Dr. Fritz, who not only showed extreme patience in guiding me through my research, but also went out of his 
way to teach me invaluable lessons about experiment design, a career in research, and the subtle art of studying and 
describing molecular interactions without minimizing their complexity.  
 The time constraint was the greatest challenge I faced this summer. Namely, we had hoped to perform more 
experiments using cells incubated in the hypoxic chamber to validate the results we collected using cobalt (II) chloride 
treatment (a hypoxia mimetic), but technical issues with the chamber itself took almost the whole summer to resolve. 
Thus, in order to see this project to completion, I will assist with the collection of data using the chamber during the 
school year, though this unfortunately means I cannot provide that comparison with cobalt chloride here. Additionally, I 
did not isolate the functional vectors for RUNX1 overexpression and knockdown in time to perform experiments with 
them, as we decided to switch to a new technique for their development later in my project. Nonetheless, the new 
constructs I helped to develop using cloning techniques and CRISPR (the latter of which I will not discuss in this report 
but nonetheless was very grateful to learn) are now validated and ready to use, which will hopefully be a straight 
forward progression from the preliminary data we collected on RUNX1 expression in hypoxia. 
 I am extremely appreciative for all that I was able to learn during the past 7 weeks. From a more practical 
standpoint, I was able to hone my skills on some techniques (e.g. Western blotting, immunofluorescence, DNA 
isolation, qPCR) and learned exciting new ones (e.g. cell culture, flow cytometry, lentiviral plasmid development, 
CRISPR). From Dr. Fritz I also learned a great deal about how to approach research in general; for instance, I soon 
learned that an interaction between two molecules in one tissue or cell type often has very little bearing on whether the 
same interaction will be observed in another. It quickly became clear that this distinction is a central theme – rather than 
a footnote - when the transcription factors being studied play such tremendous roles in cell lineage determination and 
maintenance. I also came to appreciate that developing biological constructs is going to alter the system being studied, 
highlighting the amount of thought that must go into minimizing the methodology’s impact on true physiologic 
phenomena. For example, the reason we developed plasmids with selectable puromycin and blasticidin markers is that 
the cells virally transfected with the original  RUNX1 overexpression vector (lacking selectable markers) demonstrated 
such a tremendous survival disadvantage that they were quickly outgrown by the cells which had not taken up the 
plasmid. Lastly, I learned to resist the temptation to employ tunnel vision when creating experiments; Dr. Fritz 
frequently emphasized that with transcriptional regulation, the question is not so much if two molecules influence one 
another as much as to what degree and in what conditions. This perspective is one I will try to assume both in my future 
research and in my future medical practice as I strive to see the interplay between the individual factors influencing a 
person’s health.  
 
 



















Breast Cancer Stem Cells. In women, breast cancer is the cause of most new cancer diagnoses and the second 
leading cause of cancer-related deaths.1 This high mortality rate is largely attributed to the frequency of metastasis and 
tumor relapse in the more malignant subtypes, which include Her2-enriched and basal-like breast cancer.2 A major 
driving force behind metastasis, relapse, and chemoresistance is the existence of breast cancer stem cells (BCSCs)3; this 
subpopulation of cancer cells adds another dimension of difficulty to our clinical approach to breast cancer as they can 
not only self-renew,  but also differentiate into non-stem-like cancer cells that can contribute significantly to a tumor’s 
overall heterogeneity (Fig. 1).4,5 Given these inherent properties, it is unsurprising that CSCs have been associated with 
initiating and furthering primary tumor growth, promoting intratumoral cell diversity, and facilitating metastases.3 
Hence, BCSCs are a promising target for therapies aiming to overcome the failure and recurrence of traditional 
treatments. By identifying regulators implicated in the maintenance or repression of the BCSC phenotype, we hope to 
elucidate microenvironments and signaling pathways that can be modulated to decrease the unpredictability and 
resistance to therapy of cancer stem cell-enriched tumors.  
Epithelial-to-Mesenchymal Transition. One process strongly linked to the development of CSCs is the epithelial-
to-mesenchymal transition (EMT). The EMT is an evolutionarily conserved transformation of epithelioid cells into 
more mesenchymal-like cells – that is, they begin to demonstrate decreased expression of tight junction molecules (e.g. 
E-cadherin) and increased migration, invasiveness, and resistance to apoptosis) (Fig. 2).6,7 The EMT has been solidly 
characterized as a process that facilitates carcinogenesis; while epithelia-derived hyperplasias and low grade tumors 
usually continue to express E-cadherin and maintain their epithelial phenotype, higher grade tumor cells will commonly 
acquire mesenchymal traits that serve to further the tumor’s ability to metastasize and become morphologically 
diverse.8,9 Further, it is thought that the EMT may specifically contribute to the aggressive nature of Her2-enriched and 
basal-like cancers.10,2 For example, studies suggest that high expression of transcriptional drivers of EMT allow basal 
and Her2-positive breast cancer cells to become trastuzumab-resistant, a notion supported by the restoration of 
chemotherapy sensitivity to resistant Basal/Her2-positive breast carcinoma cells following lentiviral knockdown of 
EMT transcription factors like SLUG and SNAIL-2.2 Similarly, inhibition of other EMT-inducing transcription factors 
such as Twist and Zeb in human and breast cells interferes with the ability of injected BCSCs to metastasize.3,11-15 
BCSCs and the EMT. Along with showing a greater degree of EMT, basal/Her2-enriched breast cancers show 
greater expression of the CD44+/CD24- phenotype classically used to identify CSCs, and it is now widely accepted that 
there is a direct relationship between these two processes (i.e. EMT and generation of CSCs) as they occur in 
carcinogenesis.16,3 Of the signaling pathways that regulate EMT, many have also been implicated in the development of 
CSCs – including Notch, hedgehog, WNT, TGF-β, and NF-κB.17 This suggests that the EMT, while serving an 
important role in normal embryogenesis, is commandeered by breast cancer cells that use it to gain stem-like features. 
The reliance of CSC development on the EMT is nuanced, with cancer cells employing the EMT to adjust phenotype 
according to the demands of the tumor microenvironment, rather than driving it to one morphological pole or the other. 
18,13,19-21 This is consistent with the understanding that CSCs must strike a balance between a) mesenchymal traits that 
support motility and a high proliferative capacity and b) epithelial traits that allow the establishment of new, cohesive 
tumors after metastasis. Because of the contribution of EMT, EMT-induced CSC generation, and the requisite fine 
tuning of the latter to breast cancer pathogenesis, the Stein lab has directed its attention to the regulators functioning 
upstream of these processes to better grasp which molecular interactions are pertinent to the dysregulation of cell 
lineage underlying breast cancer severity.  
RUNX1 and breast cancer. At the forefront of this investigation is R1, one of a family of Runt-related 
transcription factors known to regulate a plethora of critical developmental processes involved in proliferation, cell 
lineage determination, and apoptosis.22,23 Each plays a role in distinct aspects of development, with unique DNA- and 
protein-binding activity that changes as a function of tissue type and biological context22 (binding domains and common 
binding partners shown in Fig. 3). RUNX expression is frequently altered in a variety of cancers, highlighting a vital 
function of these transcription factors in tumor suppression that set the stage for this study. The lab has specifically 
focused on RUNX1 because mutations of this factor, while long associated with leukemias (consistent with its role in 
regulating hematopoietic lineage), have more recently been implicated in breast cancer, a finding that corroborates 
proposed involvement of RUNX1 in the maintenance of the mammary epithelial phenotype.24-27 RUNX1 expression has 
been shown to decrease with increasing breast cancer malignance, and, conversely, patients with tumors exhibiting 
lower levels of RUNX1 have a poorer prognosis than those with higher RUNX1 levels (Fig. 4).10 In addition to 
demonstrating aberrant expression patterns, RUNX1 and one of its critical cofactors, core-binding factor beta (CBFβ), 
are both frequently mutated in cancer – including breast cancer (Fig. 5).28 
Runx1, EMT, and BCSCs. Following RUNX1 knockdown in the breast cancer cell line MCF10A, our lab has 
observed an upregulation of genes related to the EMT accompanied by loss of epithelial features, such as decreased E-
cadherin expression; notably, overexpression of RUNX1 rescued this phenotype by driving the mesenchymal-to-
epithelial transition (MET).10 RUNX1 expression in MCF10A has also been shown to decrease after induction of EMT 
with TGF-β treatment and growth factor depletion, suggesting that there are pathways that allow RUNX1 and regulators 
of the EMT to reciprocally influence one another. In addition to demonstrating that RUNX1 level is decreased by EMT, 
our lab has also found lower RUNX1 expression in BCSCs isolated from premalignant MCF10AT1 cells using FACS, 
and knockdown of RUNX1 led to increased features of stemness.3 Together, these findings identify RUNX1 as a 
potential suppressor of EMT and the acquisition of stem-like properties by breast cancer cells. However, the specific 
pathways and conditions eliciting impairment of RUNX1’s protective functions in breast cancer is not yet known. This 
gap in knowledge served as the impetus for the project described here.  In exploring potential external influences on this 
system, several cases emerged from the literature that pointed to tumor-associated hypoxia as a likely candidate for the 
suppression of RUNX1 in breast tissue: 
First, several studies have described interactions between RUNX transcription factors and Hypoxia Inducible 
Factor-1α (HIF-1α). These have been noted in a variety of settings and with numerous outcomes, depending on tissue 
type and metabolic conditions.29 HIF-1α  is the primary mediator of cellular response to hypoxic conditions, allowing 
cells to survive and adapt.30 HIF-1α function is beneficial in physiologic instances of hypoxia, but its upregulation in the 
hypoxic tumor microenvironment (TME) allows tumor cells to persist even as they overgrow local oxygen supply – and 
is thus associated with poor prognosis.23 This means that molecules that prevent the degradation of HIF-1α have 
oncogenic potential while those that degrade or inhibit HIF-1α have tumor suppressing function.31 RUNX1 is one such 
factor that blocks the transcriptional activity of HIF-1α in a dose-dependent manner.32 However, the relationship 
between HIF-1α and RUNX1 is not linear; while co-immunoprecipitation and GST pull-down assays have shown that 
the two directly interact, and while RUNX1 overexpression interferes with HIF-1α binding to its known DNA targets, 
HIF-1α actually promotes the activity of RUNX1.32,23 Furthermore, HIF-1α interacts with a number of other molecules 
that differentially modify RUNX1 activity, meaning that a more complete study of the connection between HIF-1α and 
RUNX1 is in order to determine how their interplay directs cellular response to the hypoxic TME.  
Second, the hypoxic tumor microenvironment (TME) is known to induce EMT and is associated with an 
enrichment of stem-like cancer cells.33,34 Subregions of hypoxia are present in all tumors, and the progression of cells 
toward the cancer stem cell phenotype and the mesenchymal end of the EMT spectrum contribute to a poorer overall 
prognosis (Fig. 6).35 The fact that hypoxia promotes EMT and acquisition of cell stemness implicates RUNX1 in cell 
response to hypoxia not only because of the growing body of evidence designating RUNX1 as a suppressor of EMT and 
CSCs, but also because the mechanism by which hypoxia induces EMT is mediated by HIF-1α.33  HIF-1α regulates 
EMT by modulating a panel of transcription factors (including ZEB, Snail, SLUG, TWIST, and Notch), some of which 
are also attributed to giving rise to the BCSC phenotype.17 BCSCs are also more directly upregulated by hypoxia via 
HIF-1α-mediated expression of ALKBH5, which demethylates NANOG mRNA to increase levels of the pluripotency 
factor.36 Exposing pre-formed BCSCs to hypoxic conditions enhances their chemoresistance, again through a HIF-
dependent mechanism.37 These correlations are illustrated in vivo as well: in clinical specimens taken from breast 
tumors, cancer cells that were located in more hypoxic regions were less differentiated and expressed higher levels of 
genes associated with CSCs, and furthermore, the cells that survive hypoxic TMEs (which are those that express high 
HIF-1α) tend to express more mesenchymal traits.34, 38-40 It is thus highly probable that RUNX1 is critical in suppressing 
EMT and BCSC development specifically in the face of hypoxia, and inversely that a process innate to certain hypoxic 
TMEs is responsible for inhibiting the anti-oncogenic effect of RUNX1 on these processes.  
Third, RUNX1 functions in a signaling pathway downstream of Transforming Growth Factor- β (TGF-β), a known 
mediator of cell response to hypoxia and inducer of EMT. TGF-β is secreted by tumor cells, reactive stromal cells, and 
platelets, and the signaling pathway it engages along with its canonical signal transducers, the SMAD proteins, is the 
most thoroughly understood promoter of the EMT.35,10 One of the primary ways TGF-β signaling induces EMT is by 
activating transcription factors like ZEB, SNAIL, and TWIST that effect the reduced expression of E-cadherin.41 
RUNX1 complexes with SMADs, and by doing so regulates genes sensitive to regulatory signals from TGF-β.10 
Additionally, TGF-β treatment of MCF-10A mammary cells reduces RUNX1 expression, and the Stein lab 
demonstrated that this RUNX1 depletion is required for induction of EMT by TGF-β. Like its association with EMT 
and BCSCs, the relationship of RUNX1 with TGF-β also indirectly links it to response to hypoxia via interaction of 
TGF-β with HIF-1α. Specifically, the HIF-1α stabilized by hypoxia has been shown to upregulate TGF-β1 and SMAD3 
in breast cancer, and application of a  HIF-1α inhibitor decreased the expression of both molecules.29 
Despite these findings that link RUNX1 to hypoxia-related processes and molecules, little is known about the 
relationship between hypoxia and RUNX1 itself. The goal of this project was to probe this relationship in the context of 
breast cancer; specifically, we hypothesized that RUNX1 plays a role in cell response to hypoxia via mediation of cell 
signaling networks involving HIF-1α and TGF-β, and that reduction of RUNX1 activity in this pathway contributes to 
the EMT and elevated population of BCSCs observed in the hypoxic TME. Our data revealed that, as in treatment with 
TGF- β, hypoxia induced by cobalt (II) chloride does result in reduced expression of RUNX1. Additionally, we 
observed several other changes accompanying cobalt (II) chloride treatment that we did not expect: decreased Lamin B1 
expression, increase in micronuclei, and downregulated CTCF. These findings suggests that there may be a degree of 
genomic instability resulting from failure of RUNX1 to suppress EMT in the hypoxic TME.  
 
Methods 
Cell culture. Two human breast cancer cell lines, MCF10A and MCF10AT1, were grown in media containing 
DMEM/F12, 5% horse serum, 10 µg/mL human insulin, 20 ng/mL recombinant hEGF, 100 ng/mL cholera toxin, 0.5 
µg/mL hydrocortisone, 50 IU/mL penicillin/50 µg/mL streptomycin, and 2 mmol/L glutamine (note: all product details 
are provided in Table 1). MCF10A cells are immortalized, non-malignant breast cells, whereas MCF10AT1 are 
MCF10A cells that have been RAS-transformed to become premalignant (Fig. 7). To all media, Accutase, and wash 
solutions used for the hypoxia treated cells, 200 µmol/L cobalt (II) chloride was added. Cobalt (II) chloride acts as a 
hypoxia mimic in that it stabilizes HIF-1α, potentially by displacing a critical Fe2+ from the active site of prolyl 
hydroxylases.42 These prolyl hydroxylases allow for Von Hippel-Lindau factor to bind and degrade HIF-1α, so their 
inhibition by Co2+ allows induction of HIF-1α-mediated cell response to hypoxia. All experiments were performed no 
more than 10 passages after cells were thawed.  
Western blotting. Cells were harvested in RIPA buffer and 2X SDS sample buffer to which cOmplete, EDTA-free 
protease inhibitors and MG132 had been added. Cells were sonicated and centrifuged, and concentration of supernatant 
was determined with Nanodrop using the Pierce BCA Protein Assay Kit to allow loading of equivalent volumes of each 
sample in 1X RIPA and 5X loading buffer onto an 8.5% acrylamide gel. After immunoblotting, gels were transferred to 
polyvinylidene difluoride membranes using a wet transfer technique. Membranes were blocked using 5% BSA / TBST 
before incubating overnight at 4°C with the following primary antibodies diluted in 5% BSA / TBST with 1/500 sodium 
azide: rabbit polyclonal to RUNX1; mouse monoclonal to E-cadherin; mouse monoclonal to Vimentin; mouse 
monoclonal to β-actin; rabbit polyclonal to ZEB1; rabbit monoclonal to CTCF;  rabbit monoclonal to RUNX2; mouse 
monoclonal to Lamin B1, and a mouse monoclonal to HIF-1α. Secondary antibodies conjugated to horseradish 
peroxidase and Clarity Western ECL Substrate  were used to visualize blots on a Chemidoc XRS+ imaging system.  
Quantitative PCR. RNA was extracted from cells with TrIzol and purified using DNase digestion. RNA was 
subjected to quantitative PCR using the Luna Universal One-Step qPCR kit. 
Immunofluorescence. Cells were grown on coverslips and fixed using methanol or 3% formaldehyde in PBS for 
10 minutes, depending on the manufacturer’s specifications. Cells were rinsed in PBS and then permeabilized for 20 
minutes in a blocking buffer (1X PBS / 5% serum, same species as secondary antibody / 0.3% Triton X-100) before 
incubating in a 1X PBS / 5% serum solution for 40 minutes. Coverslips were incubated overnight at 4°C with the 
following primary antibodies diluted in 1X PBS, 1% BSA, and 0.3% Triton X-100: rabbit polyclonal to RUNX1; mouse 
monoclonal to Lamin B1;  rabbit monoclonal to Lamin B1; mouse monoclonal to E-cadherin;  rabbit monoclonal to 
cleaved caspase-3. Specimens were rinsed with PBS and incubated in fluorochrome-conjugated secondary antibody 
(diluted in same solution used to dilute primary) for 2 hours in the dark; for rabbit polyclonal antibodies, a goat anti-
rabbit IgG (H+L) secondary antibody was used, and for mouse polyclonal antibody, a goat anti-mouse IgG (H+L) 
secondary antibody was used. Coverslips were rinsed in PBS and Prolong Gold + DAPI was added before imaging with 
immunofluorescence microscopy. 
Flow cytometry. Cells were grown to subconfluency and detached from plates with 10-15 minute treatments of 
Accutase followed by neutralization with an equivalent volume of serum. Cells were centrifuged and resuspended in 
serum to obtain a cell count that was used to isolate 1 x 106 cells per sample. Cells were centrifuged again and 
resuspended in equivalent volumes of serum, to which the antibodies CD24 and CD44 were added and incubated for 20 
minutes. Cells were centrifuged and resuspended in PBS/FBS twice to remove antibody and then passed through a 40-
micron filter to isolate single cells. These were centrifuged once more before flow cytometry was performed using the 
pre-determined optimized conditions.24,43,44 
Lentiviral plasmid preparation. Two plasmids, one with a puromycin selectable marker (pCW57-MCS1-2A-
MCS2) and the other with a blasticidin selectable marker (pCW57-MCS1-P2A-MCS2) were amplified in bacteria 
(STBL3), isolated with a Miniprep kit, and then digested with EcoR1. PCR was used to add overhangs complementary 
to the EcoR1 site to two vectors – one with RUNX1 and another with RUNX1 P2A GFP. The PCR products were run 
on an agarose gel and isolated using gel extraction before being purified. The Gibson Assembly Reaction was used to 
insert the purified PCR product into each of the plasmids, and the resulting constructs were transformed into bacteria in 
LB+Amp. Plasmids were isolated from bacteria and sequenced to ensure correct assembly.   
 
Results 
Influence of hypoxia on RUNX1 and associated factors. Western blotting showed that HIF-1α was upregulated 
in both treated MCF10A and MCF10AT1 cells, indicating success of its stabilization by cobalt (II) chloride (Fig. 8). 
Blotting also revealed that both cell lines treated with cobalt (II) chloride at a concentration of 200 µM for 3 and 7 days 
showed a downregulation of RUNX1.The effect was far more prominent after treatment with 200 µM cobalt (II) 
chloride than with lower concentrations; MCF10A cells demonstrated a subtle decrease in RUNX1 at 3,4, and 7 days of 
100 µM treatment, while MCF10AT1 cells demonstrated a slightly greater reduction in RUNX1. Notably, both cell 
lines appear to have a greater reduction of RUNX1 in the 3 day treatments of 100 µM cobalt (II) chloride than in the 4 
and 7 day treatments, suggesting the possibility of a delayed compensatory mechanism fronted by the cell after partial 
loss of critical RUNX1 function. Blotting results were supported by immunofluorescence, which showed decreased 
RUNX1 signal accompanying cobalt (II) chloride treatment.  
Analysis of qPCR results revealed that hypoxia also leads to changes in the expression of genes regulated by 
RUNX1, such as MALAT1, Lamin B1, and LIFR (Fig. 9). Both 3 and 7 day treatments of cobalt (II) chloride led to 
enhanced expression of MALAT1 (a large nc-RNA with oncogenic potential) and LIFR (a receptor involved in 
differentiation and proliferation), and a decrease in LaminB1 (a nuclear envelope protein to be discussed further below). 
This is consistent with recent ChIP-seq and RNA-seq analyses performed by the lab showing that knockdown of 
RUNX1 led to increased MALAT1 and LIFR and decreased LaminB1. However, no changes were observed for EMT 
markers like E-cadherin, vimentin, and fibronectin-1 at the mRNA level. In contrast, Western blotting did show that the 
protein levels of the mesenchymal marker vimentin increased with cobalt (II) chloride treatment, and that the effect was 
enhanced at longer treatments for the MCF10AT1 cells. Levels of the epithelial cell marker E-cadherin were reduced in 
longer treatments of cobalt (II) chloride. Both of these indicate that EMT does not occur immediately in hypoxia, but 
rather with longer term exposures. Alternatively, this poses questions as to whether hypoxia effects changes in RNA and 
protein levels at different times – with RNA levels changing at a timepoint earlier than we analyzed – and whether 
regulation is occurring in a largely post-translational manner, as suggested by the contrasting data for vimentin. 
Supplementing the qPCR identification of Lamin B1 mRNA downregulation with hypoxia, Western blot also revealed 
that treatment led to decreases in Lamin B1 protein. The immunofluorescent staining for Lamin B1 was less prominent 
in the treated cells as well, confirming its reduction by Cobalt (II) chloride-induced hypoxia (Fig. 10). While we 
attempted to co-stain for Lamin B1 and RUNX1, cleaved caspase (a marker of apoptosis), and E-cadherin, we were 
unable to visualize Lamin B1 with other proteins because the Lamin B1 antibody required fixation in methanol while 
the rest were optimized for use with formaldehyde-fixed cells. 
Western blot additionally demonstrated a downregulation of CTCF and ZEB1 with cobalt (II) chloride treatment. 
The alteration of CTCF levels was surprising, given that CTCF was originally selected as a control, and provided 
unexpected insight as to the effects of hypoxia on genomic stability – to be discussed further below. ZEB1 
downregulation was similarly unexpected, due to the known role of ZEB1 in promoting EMT and stem-related 
processes (figure 7). Preceding data showed that RUNX1 binds the ZEB1 promoter and downregulates its expression. 
Further, level of ZEB1 mRNA is reduced in cells where RUNX1 has been overexpressed, and increased in cells with 
RUNX1 knockdown by short hairpin RNA (shRNA) (Fig. 11). This differential relationship between RUNX1 and 
ZEB1 could have its roots in the experimental procedure, necessitating validation with hypoxic chamber use. 
A qPCR analysis of BCSC markers allowed us to observe the effect of hypoxia on the development of a population 
of breast cancer stem cells. Multiple isoforms of the CD44 marker exist: the CD44s is a marker of BCSCs, while the 
CD44v is associated with non-BCSCs. Hypoxia produced an enrichment of cells with the CD44s marker and reduced 
cells expressing CD44v, indicating that cells did in fact show increased stemness following hypoxia treatment (Fig. 12).  
 Induction of genome instability by hypoxia.  Immunofluorescent staining was performed and the morphology 
between the treated and untreated cells was compared. We observed that the hypoxia-treated cells demonstrated an 
increased incidence of micronuclei (Fig. 13). Further, treatment of cells with cobalt (II) chloride for greater durations 
translated into an increasing percentage of cells with associated micronuclei. Treated cells also demonstrated a more 
polymorphic appearance, with greater variety in nuclear size and shape.  
Validation of RUNX1 overexpression constructs. Flow cytometry showed that compared to untreated cells, 
treated cells had greater CD44+ expression, a marker of breast cancer cell stemness, but the other common stemness 
marker, CD24+, did not stain. Sequencing of PCR products for the lentiviral plasmid preparation showed that both the 
puromycin and blasticidin plasmids had successfully incorporated the RUNX1 gene, but that the RUNX1 GFP P2A 
gene had been inserted with mutations in the GFP domain. The Sanger sequencing of the pCW57 vector showing 
successful insertion of RUNX1 can be seen in Fig. 14. When these puromycin and blasticidin plasmids were used for 
lentiviral transfection (not described here) of MCF10A cells in the appropriate selection antibiotic, microscopy showed 
growth of cells, indicating the successful delivery of DNA with resistance-conferring sequences (Fig. 14).  
Additionally, sequencing showed that amplification of a hygromycin plasmid for constitutive RUNX1 expression 
was successful, meaning effects of inducible and constitutive RUNX1 expression can be compared in the future under 
different conditions.  
 
Discussion 
All too often, breast cancer treatments prove to be ineffective, and as a result we see a mortality rate that is 
overwhelming compared to other cancers. The physical, emotional, and financial burdens of high grade breast cancers 
on patients underscores the need to tackle this family of diseases head on. This can be done by addressing the most 
therapy-resistant aspects of breast tumors, which include the propensity of the aggressive subtypes to develop stemness 
and undergo EMT. The present project is part of a much larger effort to uncover molecular targets implicated in these 
two processes and to identify conditions that promote or prevent them, with the hope that any factors elucidated can be 
used to eliminate the most resistant subpopulations of breast cancer cells. In this study, we found that RUNX1 is in fact 
downregulated in hypoxia, and thus, its reduction is likely to account for a degree of EMT and acquisition of stemness 
observed in cells hypoxic TMEs. All of this was consistent with pre-existing evidence showing that RUNX1 interacts 
with factors known to directly effect changes following hypoxia, such as HIF-1α and TGF-β. The results described here 
provide additional clarity to the involvement of RUNX1 in breast cancer, facilitating its future use in therapeutic 
strategies.  
Further, we found that cobalt (II) chloride treatment was associated with increased frequency of micronuclei. This 
corroborates a previous study by Snyder and Diehl45 which showed that the reduction of oxygen levels in a mouse 
enclosure from 21% (normoxic conditions) to 7.5% for up to a week resulted in mouse bone marrow cells showing a 
statistically significant 0.15% increase in micronuclei. Additionally, an increased frequency of chromatin bridges has 
been observed in fibroblasts incubated in 0.2% oxygen following genome insult with Gy irradiation – structures known 
to fragment to produce micronuclei (Fig. 15).46,47 It is well known that hypoxia destabilizes the genome through 
decreased expression of DNA repair genes, oncogene amplification, DNA replication stress, and downregulated DNA 
damage checkpoint signaling. Our finding of micronuclei induction suggests that resulting genomic reorganization and 
modification of nuclear structures also feed into hypoxia-induced genetic aberrancy.46 We conjecture that the observed 
genomic reorganization potentially occurs as a result of TGF-β signaling now being uninterrupted by RUNX1.10 It has 
been established that TGF-β-induced EMT leads to mitotic defects (including suppressed expression of the nuclear 
envelope protein Lamin B1) in conditions where persistent proliferation is not halted, and further that these mitotic 
defects may be a root cause of genomic instability seen in tumor cells where EMT is underway (Fig. 16).35 
Cobalt (II) chloride treatment also led to a downregulation of Lamin B1 and CTCF. Loss of Lamin B1 from the 
nucleus is one factor known to increase presence of binucleated cells and micronuclei, thus implicated RUNX1 
depletion in the formation of both structures through unchecked TGF-β activity. CTCF, like Lamin B1, is also critical 
for maintaining genomic stability, and its downregulation has been observed in models of breast cancer outside of 
hypoxia.48 Among many other chromosome-modulating functions, including the arrangement of chromatin into 
localized loops and larger topological regions, the insulator protein functions in homologous recombination repair of 
double-strand DNA breaks.49 Hence, downregulation of CTCF in breast cancer leads to a breakdown of both DNA 
integrity and organization. It is not yet known how hypoxia, RUNX1, or TGF-β factor into CTCF repair of DNA 
damage or its reduction in breast cancer, but these relationships warrants further investigation considering the 
importance of CTCF in establishing chromosomal order.  
It is possible that RUNX1 elicits genome-stabilizing effects that counteract those of heightened TGF-β signaling 
through mechanisms other than its interaction with SMADs. Though similarities between members of the RUNX family 
and between RUNX factors in different tissues cannot be assumed, future studies of RUNX1 may benefit from drawing 
inspiration from them.  For example, RUNX1 in hemopoietic cells helps to promote p53 dependent apoptosis in 
response to DNA damage, outlining the possibility that reduction of RUNX1 may lead to increased survival of breast 
cancer cells in which enhanced TGF- β signaling has caused genomic instability.50,51 In another example of RUNX 
proteins suppressing tumorigenic processes initiated by TGF- β, both RUNX1 and RUNX3 are induced by TGF- β to 
interact with forkhead box protein O3 (FOXO3A) to promote the expression of a pro-apoptotic mediator in specific 
tissues.23 RUNX3 also modulates TGF-β activity by enhancing activity of heme oxygenase 1 (HMOX1), which 
responds to oxidative DNA damage such as the double-stranded breaks caused by TGF- β when dysregulated in 
cancer.52  
Two other factors require further study with respect to role of RUNX1 in hypoxia: CBFB and NOTCH. CBFB 
forms a complex with RUNX1 in the nucleus that suppresses the transcription of genes in the NOTCH signaling 
pathway.53 This is significant because enhanced Notch expression underlies breast cancer qualities such as anchorage 
independent growth and tumorigenicity. Furthermore, Notch may play a distinct role in mediating these processes in the 
hypoxia TME in breast cancer; Notch genes are upregulated by HIF-1α, and this hypoxia-induced Notch activation is 
critical for maintaining the undifferentiated cell state in stem and precursor cells.54 In addition to complexing with 
RUNX to suppress NOTCH, CBFB also regulates level of RUNX1 by binding its mRNA to enhance its translation - 
evidenced by the depletion of RUNX1 that is observed when CBFB is knocked down in MCF10A cells.53 Thus, CBFB 
is a promising candidate for paving the connection between hypoxia and maintenance of cell lineage by RUNX1.   
In addition to pursuing a deeper understanding of RUNX1 role in suppressing DNA destabilization by TGF-β-
induced EMT in hypoxia, and in studying RUNX1 relationship to potential CBFB-Notch interactions in hypoxia, future 
steps for this project will include experiments using a hypoxic chamber to validate the results collected using cobalt (II) 
chloride. It is possible that cobalt (II) chloride, which mimics hypoxia by stabilizing HIF-1α, may not accurately show 
the full scope of hypoxia’s effect on RUNX1 given that cells employ responses to hypoxia that are independent of  HIF-
1α, and these too may be influencing RUNX1 or other parts of the pathway discussed above. Further, the inducible 
plasmids developed can now be used to determine whether an epithelioid phenotype, genomic stability, and appropriate 
differentiation of cells are restored to hypoxic cells when RUNX1is overexpressed in hypoxia. These experiments will 
help to pinpoint the function of RUNX1 in cell response to hypoxia and inversely, the effects of its absence on cancer 




Figure 1. Advancement of tumor severity via transformation of primary tumor cells into a sub-population of cancer 
stem cells, which show enhanced abilities of self-renewal, proliferation, and resistance to chemotherapy. Adapted from 
‘cancer stem cells in osteosarcoma,’ by H.K. Brown, M. Tellez-Gabriel, and D. Heymann, 2017, Cancer Letters, 386: 
189-195.  
 
Figure 2. Cellular features and markers of the epithelial to mesenchymal transition.  Adapted from ‘epithelial to 
mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and 
potential therapeutic interventions,’ by L.S. Aroeira, A. Aguilera, et al., 2007, Journal of the American Society of 




Figure 3. Binding domains in the sequences of RUNX1, RUNX2, and RUNX3. Schematics show a conserved binding 
site for the important RUNX cofactor CBFβ, for the TGF-β messengers known as the SMADs, and an assortment of 
other proteins that interact with RUNX factors to influence their DNA-binding activity. Adapted from ‘RUNX1-
dependent mechanisms in biological control and dysregulation in cancer,’ by D. Hong and A.J. Fritz, 2018, Journal of 
Cell Physiology, 234(6), p. 8599.    
 
Figure 4. Reduced RUNX1 expression is associated with breast cancer subtypes with poor prognosis. The top three 
charts show three different datasets indicating lower survival rate in patients with lower RUNX1. The lower charts show 
that RUNX1 mRNA is depleted in the more aggressive subtypes of breast cancer (left) and in more advanced stages of 
breast cancer (right). Adapted from ‘RUNX1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to 
mesenchymal transition,’ by D. Hong and T. Messier, 2017, Oncotarget, 8(11).  
 
 
Figure 5. Mutations of RUNX1 and CBFβ (exemplified in protein structures on right) are common in breast cancer – 
particularly those subtypes listed in the figure above (left). Adapted from ‘RUNX1-dependent mechanisms in biological 
control and dysregulation in cancer,’ by D. Hong and A.J. Fritz, 2018, Journal of Cell Physiology, 234(6), p. 8603. 
 
Figure 6. Hypoxia induces EMT and cancer stemness through the regulation of EMT- and CSC-mediating transcription 
factors by HIF-1α. Adapted from ‘genomic instability is induced by persistent proliferation of cells undergoing 








Table 1. Details for products in methods section. 
Product Product Details  
Cell culture  
DMEM/F12 Hyclone: SH30271, Thermo Fisher Scientific 
Horse serum Gibco: 16050, Thermo Fisher Scientific 
Human insulin Sigma-Aldrich, I-1882 
Recombinant hEGF Peprotech, AF-100-15 
Cholera toxin Sigma-Aldrich, C-8052 
Hydrocortisone Sigma-Aldrich, H-0888 
Penicillin/Streptomycin Life Technologies, 15140-122 
Glutamine  Life Technologies, 25030-081 
Cobalt (II) Chloride  Sigma Aldrich, C8661 
Western blotting 
EDTA-free protease inhibitors Roche Diagnostics 
MG132 EMD Millipore 
Polyvinylidene difluoride membranes EMD Millipore 
Membrane wet transfer kit BioRad Laboratories 
Rabbit polyclonal to RUNX1 Cell Signaling Technology: #4334, 1:1,1000 
Mouse primary monoclonal antibody to E-
cadherin 
Santa Cruz Biotechnology: sc21791, 1:1,000 
Mouse primary monoclonal antibody to Vimentin Santa Cruz Biotechnology: sc-6260, 1:1,000 
Mouse primary monoclonal antibody to β-actin Cell Signaling Technology: #3700, 1:1,000 
Rabbit primary polyclonal antibody to ZEB1 Sigma-Aldrich: HPA027524-100 UL, 1:1,000 
Rabbit primary monoclonal antibody to CTCF Cell Signaling: #3418, 1:1,000 
Rabbit primary monoclonal antibody to RUNX2 Cell Signaling: 12556, 1:1,000 
Mouse primary monoclonal antibody to Lamin B1 Cell Signaling: #68591, 1:1,1000 
Mouse primary monoclonal antibody to HIF-1α Cell Signaling: NB-100-105, 1:1,000 
Horseradish peroxidase-conjugated secondary 
antibodies  
Santa Cruz Biotechnology 
Clarity Western ECL Substrate Bio-Rad Laboratories 
Chemidoc XRS+ imaging system Bio-Rad Laboratories 
Quantitative PCR 
TrIzol Life Technologies 
DNase digestion technique Zymo Research 
Immunofluorescence  
Rabbit primary polyclonal antibody to RUNX1 Cell Signaling Technology: #4334, 1:200, 
formaldehyde 
Mouse primary monoclonal antibody to Lamin B1 Cell Signaling: #68591, 1:200, methanol 
Rabbit primary monoclonal antibody to Lamin B1 Abcam: ab194106, 1:100, methanol 
Mouse primary monoclonal antibody to E-
cadherin 
Cell Signaling: #14472, 1:50, formaldehyde 
Rabbit primary monoclonal antibody to cleaved 
caspase-3 
Cell Signaling: #9664, 1:400, formaldehyde 
Goat anti-rabbit IgG (H+L) secondary antibody Alexa Fluor 594 conjugate, Life Technologies A-11037 
Goat anti-mouse IgG (H+L) secondary antibody Alexa Fluor 488 conjugate, Life Technologies A-11029 
Prolong Gold + DAPI Life Technologies-Molecular Probes 
Flow cytometry  
CD24 antibody PE-Cy7, BioLegend 311120 
CD44 antibody APC, BD Pharmigen 559942) 
Lentiviral plasmid preparation 
pCW57-MCS1-2A-MCS2 Addgene: #71782 
pCW57-MCS1-P2A-MCS2 Addgene: #80921 
Miniprep kit Zyppy Miniprep, Zymo Research 
Gel extraction kit Zymoclean Gel Recovery, Zymo Research 
DNA purification kit  DNA Clean and Concentrator-5, Zymo Research 
 
Figure 7. Cell lines used and the morphology and karyotype of each. 
.  
Figure 8. Western blot showing levels of RUNX1, vimentin, E-cadherin, HIF-1α, and β-actin in MCF10A and 
MCF10AT1 cells after 3,4, and 7 days of cobalt (II) chloride treatment (0, 100, 200 µM).  
 
 
Figure 9. Fold change in transcript levels (relative to POL2RA) of RUNX1 targets MALAT1, Lamin B1, and LIFR 
after 3 and 7 days of cobalt (II) chloride treatment.  
 
Figure 10. Lamin B1 staining of untreated cells compared to cells treated with cobalt (II) chloride for 3 days.  
 
 
Figure 11. RUNX1 regulation of ZEB1 expression. On the left, ChIP-qPCR (above) shows that RUNX1 binds directly 
to the promoter of ZEB1 to influence its transcription, and blots (below) show that ZEB1 levels are lower when RUNX1 
is overexpressed and higher when RUNX1 is knocked down. To the right is a diagram of the involvement of ZEB1 in 
promoting stemness and EMT, which contribute to tumor growth, migration, and invasion. Adapted from ‘RUNX1-
dependent mechanisms in biological control and dysregulation in cancer,’ by D. Hong and A.J. Fritz, 2018, Journal of 
Cell Physiology, 234(6), p. 8603. 
               
Figure 12. Fold change in expression of CD44s and CD44v (relative to POL2RA) in cells treated with cobalt (II) 
chloride for 3 and 7 days.  
                  
Figure 13. Treatment of MCF10AT1 cells with cobalt (II) chloride induces the formation of micronuclei. Left image of 
immunofluorescence shows RUNX1 staining in nuclei (pink), several of which have nearby micronuclei (arrows). The 
figure to the right shows the relative frequency of micronuclei in treated and untreated cells, with a greater occurrence 
of micronuclei being observed in the treated cells. Error bars are absent due to lack of sufficient replicates, but ongoing 
research will provide additional trials to supplement these initial findings.  
                
 
Figure 14. Verification of RUNX1 insertion into overexpression plasmids and lentiviral transfection of plasmids into 
MCF0A cells. The above diagram shows Sanger sequencing of pCW57 vector after insertion of RUNX1 gene. Below 
are bright field images showing the growth of MCF10A cells in selection media after lentiviral transfection with 
puromycin (above) and blasticidin (below) plasmids containing RUNX1. From left to right, concentrations of virus 
added to cells increases from 0 µL to 20 µL; the greater density of MCF10A cells in puromycin+ and blasticidin+ media 
with greater volume of virus added suggests successful incorporation of RUNX1 overexpression vector into cell 
genomes.  
 
Figure 15. Chromatin bridges, the frequency of which increases under hypoxic conditions, fragment and result in the 
formation of micronuclei. Adapted from ‘resolution of anaphase bridges in cancer cells,’ by D.R. Hoffelder, L. Luo et 
al., 2004, Chromosoma, 112: 392.  
 
Figure 16. Cells undergoing TGF-β-induced EMT that continue to proliferate demonstrate genomic instability. Adapted 
from ‘genomic instability is induced by persistent proliferation of cells undergoing epithelial-to-mesenchymal 
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